Filing Flows › Novavax (NVAX) › R&D spending
Novavax (NVAX) R&D spending by quarter
Novavax's R&D spending was $52.4M in Q3 2026 (third quarter 2026), -26% from Q2 2026. Over the last 7 quarters it ranged from $52.4M (Q3 2026) to $98.3M (Q3 2025).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $52.4M | -26% | -47% |
| Q2 2026 | $70.7M | -26% | -11% |
| Q1 2026 | $95.5M | +26% | +7% |
| Q4 2025 | $75.9M | -23% | — |
| Q3 2025 | $98.3M | +24% | — |
| Q2 2025 | $79.2M | -11% | — |
| Q1 2025 | $88.9M | — | — |
Q3 2026 at a glance
Novavax, Q3 2026: revenue $68.3M (-3% year over year), operating margin -45.8%, net loss $31.4M, operating cash flow −$94.2M. The chart follows the revenue to costs, profit and cash.
Questions
What is Novavax's R&D spending?
Novavax's R&D spending was $52.4M in Q3 2026 (third quarter 2026), -26% from Q2 2026.
How has Novavax's R&D spending changed?
Over the last 7 quarters it ranged from $52.4M (Q3 2026) to $98.3M (Q3 2025).